CG Oncology (CGON) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed CG Oncology (CGON) over the past year, gaining 207.9% versus a gain of 64.2%. CG Oncology is the larger company by market cap ($5.53 billion vs $3.93 billion), about 1.4 times the size. Relay Therapeutics converts more of its revenue into profit, with a net margin of -1800.6% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | RLAY |
|---|---|---|
| Share price | $62.38 | $17.95 |
| Market cap | $5.53B | $3.93B |
| 1-day change | -1.98% | -4.22% |
| YTD return | +50.24% | +112.17% |
| 1-year return | +64.16% | +207.89% |
| 5-year return | — | -47.38% |
| EPS (TTM) | $-2.69 | $-1.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $15.36M |
| Revenue growth (YoY) | +254.70% | +53.44% |
| Net income (latest FY) | $-161.00M | $-276.48M |
| Operating margin | -4722.13% | -1971.59% |
| Net margin | -3985.02% | -1800.58% |
| 52-week high | $80.97 | $21.27 |
| 52-week low | $35.80 | $5.83 |
| Distance from 52-week high | -22.96% | -15.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.01% | +53.65% |
| Average volume | 891.79K | 2.81M |
| Shares outstanding | 88.64M | 219.14M |
| Employees | 142 | 202 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed CGON by 143.7 percentage points over the past year.
- Relay Therapeutics is more profitable, keeping -1800.6 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +53.44%).
- The two companies sit in different sectors: CG Oncology in Healthcare and Relay Therapeutics in Health Care.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Healthcare · Biotechnology · 142 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
CGON vs RLAY FAQ
Which is bigger, CG Oncology or Relay Therapeutics?
CG Oncology (CGON) is larger, with a market capitalization of $5.53B compared with $3.93B for Relay Therapeutics (RLAY).
Which stock has performed better over the past year, CGON or RLAY?
RLAY returned +207.89% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Relay Therapeutics in the same industry?
No. CG Oncology is in the Healthcare sector, while Relay Therapeutics is in Health Care.